News from tarix orphan llc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 12, 2017, 08:00 ET Tarix Orphan Granted Orphan Drug Status by the EMA for TXA127 as Potential Treatment for Epidermolysis Bullosa (EB)

Tarix Orphan LLC today announced that the European Medicines Agency has granted Orphan Drug status to the company's lead compound, TXA127, for the...


Jan 18, 2017, 07:00 ET Tarix Orphan Receives Rare Pediatric Disease Designation for TXA127 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted a Rare Pediatric Disease (RPD) designation for the company's...


Sep 07, 2016, 08:30 ET Tarix Orphan Receives Orphan Drug Status for TXA127 for Genetic Skin Disorder Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Tarix Orphan LLC today announced that the company has received Orphan Drug Status from the U.S. Food and Drug Administration for TXA127 as a...


Jun 27, 2016, 08:30 ET Tarix Orphan Announces Positive Results with TXA127 in Animal Model of Dystrophic Epidermolysis Bullosa (DEB)

Tarix Orphan LLC today announced that the company's lead compound, TXA127, has shown positive preclinical results in the C7-hypomorphic mouse model...


Feb 17, 2016, 08:00 ET Tarix Orphan Granted Orphan Drug Status for TXA127 as Potential Treatment for Congenital Muscular Dystrophy (MDC1A)

Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company's lead compound, TXA127,...


Oct 06, 2015, 08:30 ET Tarix Orphan Receives FDA Fast Track Designation for TXA127 as Potential Treatment for Duchenne Muscular Dystrophy

Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, ...